Naaju Breaking News, Live Updates, Latest Headlines, Viral News, Top Stories, Trending Topics, Videos
[ad_1]
Pharmaceutical Pfizer announced on Monday that its vaccine against covid-19 is 90% efficientaccording to the first analysis of its Phase 3 trial.
This news sparked a lot of optimism, as some specialists had said that a a formula that reaches 60% vaccination would already be a positive result to deal with the pandemic.
Pharmaceutical Pfizer is expected to be the first company to officially seek approval for its vaccine.
These are the 6 most important facts published by the New York Times to know the pfizer vaccine:
1) The opinion of scientists
The latest tests began in July, with 44,000 participants worldwide. Half of them received the vaccine, while the rest were injected with a saltwater placebo. Scientists then waited to see which volunteers contracted the disease to determine whether the vaccine was effective or not.
Only 94 people fell ill. A group of specialists outside of Pfizer and BioNtech have come to the conclusion that the effectiveness is over 90%.
2) What should be done during rehearsals?
Testing will continue until 164 people contract COVID-19. Thereafter, the study will be considered completed.
3) The first people to receive the vaccine
Albert Bourla, CEO of Pfizer, explained that between 30 and 40 million doses could be produced before the end of the year. The criteria for deciding who will receive these doses have not yet been determined, but different jurisdictions globally have expressed their willingness to prioritize groups at highest risk.
4) When could you receive the approval
From the pharmacy, they assured that the third week of November they will place the order. Information remains to be collected for the two months of the phase 3 trials.
5) Work for the elderly?
The results still do not allow to conclude whether immunity will be strong in this demographic group. There are also volunteers over 65 in the studies.
6) Be the end of the mask?
They assure not, because it will not be available en masse for several months. In addition, there is no information on whether the vaccine prevents asymptomatic transmission of the virus, nor on the possibilities of preventing severe cases of the disease.
.
[ad_2]
Source link
